Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

targeting two separate epigenetic pathways simultaneously, the combination of drugs targeting DNA methylation and histone deacetylation can either increase the susceptibility of cancer cells to standard chemotherapy or act as a potent therapeutic regimen in its own right.

About Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a cancer of the lymphatic system that begins in the lymph nodes and progresses to other organs, including the lungs, liver, bone and bone marrow. It is characterized by the presence of Reed-Sternberg cells. Currently, there is no known cause of the disease, but epigenetic alterations including changes in histone acetylation, have been identified. In addition, the Epstein-Barr virus, HIV and familial history are known risk factors. The disease is slightly more prevalent in men than women, and the median age of diagnosis is 38.

About Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) are any of a large group of cancers of the immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever, and weight loss. There are many different types of NHL, which can be divided into aggressive (fast-growing) and indolent (slow-growing) types and can be classified as either B-cell or T-cell NHL. B-cell NHLs include Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell NHLs include mycosis fungoides, anaplastic large cell lymphoma, and precursor

T-lymphoblastic lymphoma. Lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation are usually B-cell NHLs. Currently, there is no known cause of the disease, but epigenetic alterations including histone acetylation, have been identified. In addition, the Epstein-Barr virus, HIV, Hepatitis-C and familial history are known risk factors.

The disease is slightly more prevalent in men then women, and i
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/14/2014)... Institute (BTI) has entered into an agreement with ... to identify novel drug candidates for the detection ... BTI,s capabilities in novel antibody discovery and Roche,s ... opening up the possibility of improved treatment for ... , The collaboration makes use of BTI,s discovery ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... physically active in middle age appears to help reduce ... dementia, suggest the findings from two new studies. ... various levels, especially in midlife, is beneficial for cognitive ... in an Alzheimer,s Association news release. "These are ... research is needed to determine the extent and nature ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... who enjoy mentally stimulating games may have bigger brains and ... The study looked at the connection between playing games such ... adults in their 50s and 60s. Researchers found that ... performed better on tests of memory and other mental functions. ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... Inc. (R) (HMS) has been closely following ... as it unfolds, especially its impact on ... yesterday on ARRA, even with the up-front investment required ... electronic health record (EHR) technology if they are to ...
... - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) ... , "Over the last while we have faced significant ... not currently able to continue to finance our clinical ... CEO. "We will be moving to a skeleton staff ...
... Oncology, Inc. ("US Oncology" or "the,Company"), one of the ... million, EBITDA of $52.3 million, Adjusted EBITDA,of $55.2 million, ... of $64.2,million for the three months ended December 31, ... ended December 31, 2008, prior to a first quarter ...
... Coalition Seeks to Increase Public Awareness and Research to ... February 28 To Be Observed Around the World With ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... of organizations led by the National Organization for Rare ...
... Manitoba and CINCINNATI, Feb. 26, 2009 Reliance,Products LP ... announce that the U.S.,Environmental Protection Agency (EPA) has approved ... the removal of arsenic, the parasites,Cryptosporidium and Giardia, and ... http://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LOGO-a ) , The EPA ...
... NEW YORK, Feb 26 Our faces are our ... emotions and are connected with three out of the ... But what happens when what you see in the ... Multimedia News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you ...
Cached Medicine News:Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 2Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 4Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 5Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 6Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 7Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 8Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 9Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 10Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 11Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 12Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 13Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 14Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 15Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 16Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 17Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 18Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 19Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 20Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 21Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 22Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 23Health News:BioMarin Supports Observance of Rare Disease Day February 28 2Health News:BioMarin Supports Observance of Rare Disease Day February 28 3Health News:BioMarin Supports Observance of Rare Disease Day February 28 4Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 2Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 3Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2